LXRX
Price
$0.71
Change
+$0.01 (+1.43%)
Updated
Apr 25, 04:59 PM (EDT)
Capitalization
257.28M
5 days until earnings call
MNKD
Price
$4.74
Change
+$0.07 (+1.50%)
Updated
Apr 25, 04:59 PM (EDT)
Capitalization
1.42B
11 days until earnings call
Ad is loading...

LXRX vs MNKD

Header iconLXRX vs MNKD Comparison
Open Charts LXRX vs MNKDBanner chart's image
Lexicon Pharmaceuticals
Price$0.71
Change+$0.01 (+1.43%)
Volume$29.04K
Capitalization257.28M
MannKind
Price$4.74
Change+$0.07 (+1.50%)
Volume$12.65K
Capitalization1.42B
LXRX vs MNKD Comparison Chart
Loading...
LXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MNKD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
LXRX vs. MNKD commentary
Apr 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LXRX is a Buy and MNKD is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 26, 2025
Stock price -- (LXRX: $0.71 vs. MNKD: $4.74)
Brand notoriety: LXRX and MNKD are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: LXRX: 43% vs. MNKD: 48%
Market capitalization -- LXRX: $257.28M vs. MNKD: $1.42B
LXRX [@Biotechnology] is valued at $257.28M. MNKD’s [@Biotechnology] market capitalization is $1.42B. The market cap for tickers in the [@Biotechnology] industry ranges from $276.16B to $0. The average market capitalization across the [@Biotechnology] industry is $2.16B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LXRX’s FA Score shows that 1 FA rating(s) are green whileMNKD’s FA Score has 0 green FA rating(s).

  • LXRX’s FA Score: 1 green, 4 red.
  • MNKD’s FA Score: 0 green, 5 red.
According to our system of comparison, LXRX is a better buy in the long-term than MNKD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LXRX’s TA Score shows that 6 TA indicator(s) are bullish while MNKD’s TA Score has 5 bullish TA indicator(s).

  • LXRX’s TA Score: 6 bullish, 4 bearish.
  • MNKD’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, both LXRX and MNKD are a good buy in the short-term.

Price Growth

LXRX (@Biotechnology) experienced а +38.96% price change this week, while MNKD (@Biotechnology) price change was +4.41% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.17%. For the same industry, the average monthly price growth was -3.10%, and the average quarterly price growth was -10.42%.

Reported Earning Dates

LXRX is expected to report earnings on Jul 31, 2025.

MNKD is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+8.17% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MNKD($1.42B) has a higher market cap than LXRX($257M). LXRX YTD gains are higher at: -4.076 vs. MNKD (-26.283). MNKD has higher annual earnings (EBITDA): 77.5M vs. LXRX (-184.29M). LXRX has more cash in the bank: 238M vs. MNKD (197M). MNKD has less debt than LXRX: MNKD (47.7M) vs LXRX (108M). MNKD has higher revenues than LXRX: MNKD (286M) vs LXRX (31.1M).
LXRXMNKDLXRX / MNKD
Capitalization257M1.42B18%
EBITDA-184.29M77.5M-238%
Gain YTD-4.076-26.28316%
P/E RatioN/A46.70-
Revenue31.1M286M11%
Total Cash238M197M121%
Total Debt108M47.7M226%
FUNDAMENTALS RATINGS
LXRX vs MNKD: Fundamental Ratings
LXRX
MNKD
OUTLOOK RATING
1..100
349
VALUATION
overvalued / fair valued / undervalued
1..100
58
Fair valued
60
Fair valued
PROFIT vs RISK RATING
1..100
10037
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
4263
P/E GROWTH RATING
1..100
1896
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LXRX's Valuation (58) in the Biotechnology industry is in the same range as MNKD (60). This means that LXRX’s stock grew similarly to MNKD’s over the last 12 months.

MNKD's Profit vs Risk Rating (37) in the Biotechnology industry is somewhat better than the same rating for LXRX (100). This means that MNKD’s stock grew somewhat faster than LXRX’s over the last 12 months.

LXRX's SMR Rating (97) in the Biotechnology industry is in the same range as MNKD (100). This means that LXRX’s stock grew similarly to MNKD’s over the last 12 months.

LXRX's Price Growth Rating (42) in the Biotechnology industry is in the same range as MNKD (63). This means that LXRX’s stock grew similarly to MNKD’s over the last 12 months.

LXRX's P/E Growth Rating (18) in the Biotechnology industry is significantly better than the same rating for MNKD (96). This means that LXRX’s stock grew significantly faster than MNKD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
LXRXMNKD
RSI
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
88%
Momentum
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
72%
MACD
ODDS (%)
Bullish Trend 5 days ago
87%
Bullish Trend 2 days ago
87%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
75%
Advances
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
82%
Declines
ODDS (%)
Bearish Trend 10 days ago
87%
Bearish Trend 18 days ago
79%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
83%
Aroon
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
72%
View a ticker or compare two or three
Ad is loading...
LXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MNKD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HGHSX37.62N/A
N/A
Hartford Healthcare R4
VMIDX22.12N/A
N/A
VALIC Company I Mid Cap Index
JHQPX31.05N/A
N/A
JPMorgan Hedged Equity R5
VAESX15.72N/A
N/A
Virtus KAR Emerging Markets Small-Cap A
SETAX15.68N/A
N/A
SEI Real Estate F (SIMT)

LXRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, LXRX has been loosely correlated with PLRX. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if LXRX jumps, then PLRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LXRX
1D Price
Change %
LXRX100%
+0.71%
PLRX - LXRX
42%
Loosely correlated
-7.01%
ABOS - LXRX
38%
Loosely correlated
-1.82%
VCYT - LXRX
37%
Loosely correlated
+0.28%
OCUL - LXRX
36%
Loosely correlated
-2.41%
RXRX - LXRX
36%
Loosely correlated
-0.35%
More

MNKD and

Correlation & Price change

A.I.dvisor indicates that over the last year, MNKD has been loosely correlated with VCYT. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if MNKD jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MNKD
1D Price
Change %
MNKD100%
+1.50%
VCYT - MNKD
44%
Loosely correlated
+0.28%
LXRX - MNKD
42%
Loosely correlated
+0.71%
INSM - MNKD
40%
Loosely correlated
+1.06%
BLUE - MNKD
38%
Loosely correlated
N/A
AMRN - MNKD
36%
Loosely correlated
-6.71%
More